Breaking News

Curis (CRIS) Gets FDA Nod to Partly Resume Leukemia Study

Curis, Inc. CRIS announced that it has received a notification from the FDA, wherein the regulatory body allowed the company to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study.
http://dlvr.it/SXYg5C